ClinicalTrials.gg
RecruitingNCT05886114HERITAGEUpdated Jun 6, 2023

A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China

An interventional study of Structured Multi-domain Intervention and Self-Guided Intervention in Cognitive Impairment, Alzheimer Disease and Vascular Cognitive Impairment, sponsored by Zhejiang University. Recruiting at 1 site in China. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by Zhejiang University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 6 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 310 studies in Cognitive Dysfunction with a site in China — 144 open to participants now, 156 under way, 8 of them phase 3. Cognitive Dysfunction · China.

Planned enrollment
8th of 191
1,200 · median 110
Started
2023
with 30 others
No phase
139 of 310
61 open now
Primary completion
2025-04
later than 23 of 155 live
Registered
149th of 310
by date

Among the 310 studies in Cognitive Dysfunction with a site in China, this one is the 8th largest by planned enrollment of the 191 interventional ones that give a count, is one of 31 that started in 2023, is one of 139 with no phase, reaches primary completion later than 23 of the 155 other live ones, and was the 149th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

144 of the 310 studies in Cognitive Dysfunction with a site in China are open now. Recruiting first, the newest first:

139 more — sign in →

All 144 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Cognitive Dysfunction with a site in China, or all of them as a file.
02

Study summary

A study conducted in Finland discovered that a multidomain intervention, consisting of physical activity, nutritional guidance, cognitive training, social activities, and management of vascular risk factors, effectively decelerated cognitive decline in healthy older adults who were at an increased risk of cognitive decline. The HERITAGE study is a 2-year clustered randomized controlled trial (clustered-RCT) that explores the efficacy of a multidomain intervention among 1200 elderly residents with a higher risk of cognitive decline and dementia in Zhejiang Province, China

Read the detailed description

The effectiveness of a multidomain lifestyle intervention on the prevention of cognitive decline and dementia have not been studied in Asian elderly at high risk of dementia conversion. Dementia is caused by both nonmodifiable genetic variables, and modifiable lifestyle risk factors. While neuroimaging biomarkers have been well documented in the neurophysiology of ageing and age-associated cognitive decline, their role as surrogate endpoints and intermediate variables between multi-domain lifestyle intervention and cognitive benefits has not been studied. The current study aims to understand brain functional and structural changes that may result from a multi-domain lifestyle intervention and whether the changes correlate with improvement in cognitive function. At risk elderly aged 60-80 years will be randomly allocated to either the control arm (self-guided management) or the intervention (multi-domain lifestyle) arm, which consists of nutritional guidance, physical exercise, cognitive training and the monitoring and management of vascular and metabolic risk factors. We hypothesize that the multi-domain lifestyle intervention will promote favorable changes in cognitive function. Moreover, such intervention will slow down the progression of cerebrovascular disease and neurodegeneration in participants in the intervention arm. Findings from the present study will shed light on the biological mechanisms of age-related cognitive decline and neurodegenerative disease. Insight obtained from the study could be translated into new targets of nonpharmacological interventions which aim at the potential causal molecular pathways implicated in ageing and age-related cognitive decline. Adaption and implementation of our findings into clinical and public health practice will further promote healthy and confident ageing among Chinese elderly, to eventually expand their health span.

03

Conditions studied

  • Cognitive Impairment
  • Alzheimer Disease
  • Vascular Cognitive Impairment
  • Dement
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Neurocognitive Disorders
  • Mental Disorder
  • Cognition Disorder
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At risk of cognitive decline: cognitive performance at the mean level or slightly lower than expected for age with no dementia (AD8>=3 and/or 5-min >, \< 11)
  • Free of physical disabilities that preclude participation in the study
  • Willing to complete all study-related activities for 24 months
  • Willing to be randomized to either lifestyle intervention group

Exclusion criteria

Exclusion Criteria:

  • Diagnosed dementia patients
  • Diagnosed major depression or other neuropsychological diseases
  • Malignant diseases
  • Symptomatic cardiovascular disease
  • Revascularization within one year
  • Severe loss of vision, hearing or communicative ability
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Structured Multi-domain Intervention

    Multi-domain structured intervention will be tailored by Chinese traditional and social norms and then conducted among the intervention group. That includes: Nutritional and dietary instruction, Cognitive training, Physical exercises, and Vascular risks monitoring and control.

    Behavioral: Structured Multi-domain Intervention

  • Experimental
    Self-Guided Intervention

    Every 6-12 months, control group will receive a regular health education campaign to encourage a healthy lifestyle and a regular health monitoring and examination of blood pressure, weight, fasting blood glucose and liposome group

    Behavioral: Self-Guided Intervention

Interventions

  • BehavioralStructured Multi-domain Intervention

    Structured Multi-domain Intervention (SMI) involves providing participants with intensive structure and support by a team of trainers to increase physical exercise, adhere to a healthy diet, cognitive training, increase intellectual/social stimulation, and better manage vascular risk factors.

    Also known as: SMI

  • BehavioralSelf-Guided Intervention

    In the Self-Guided Intervention (SGI), education about the importance of a healthy lifestyle as a preventive strategy and support to encourage change will be provided.

    Also known as: SGI

06

What researchers measure

Primary outcomes

  1. Global Cognition

    Globe cognitive performance (composite z-score) measured by comprehensive Neuropsychological Test Battery (NTB)

    Time frame: Up to 2 years

  2. Domain-specific Cognition

    NTB domain-specific cognitive performance (composite z-score) for memory, executive function, attention, language, visuomotor speed and visuoconstruction.

    Time frame: Up to 2 years

Secondary outcomes

  1. Neuroimaging: MRA

    Changes in brain blood flow assessed by magnetic resonance angiography(MRA)

    Time frame: Up to 2 years

  2. Neuroimaging: MRI

    Changes in brain structural integrity (gray matter volume loss, white matter microstructure degradation and increase of cerebrovascular markers) assessed by T1-weighted Magnetization Prepared Rapid Gradient Recalled Echo, Fluid Attenuated Inversion Recovery (FLAIR), T2-weighted, and Susceptibility Weighted Imaging sequences

    Time frame: Up to 2 years

  3. Neuroimaging: fMRI

    Changes in brain functional networks assessed by fMRI

    Time frame: Up to 2 years

  4. Number of participants with Laboratory Values /Blood markers

    Blood samples will be collected from all patients in tubes with ethylenediaminetetraacetic acid 0.1%. Changes in Novel and accessible blood markers to monitor AD- and CeVD- associated pathologies. Plasma concentrations of cardiac markers (High-sensitive cardiac troponin T (hs Troponin T), N-terminal pro b-type natriuretic peptide (NT-proBNP) and Growth/differentiation factor 15 (GDF 15)), and peripheral biomarkers of Aβ, tau and synaptic pathology, oxidative stress, endothelial/cardiovascular injury and degenerative protein modifications (DPMs) damaged proteins will be measured by laboratory testings.

    Time frame: Up to 2 years

  5. Incident dementia

    Incidence of dementia. Dementia diagnoses will be made by CDR and DSM-IV criteria.

    Time frame: Up to 2 years

  6. Clinical Dementia Rating-Sum of Boxes (CDR-SB)

    The Clinical Dementia Rating-Sum of Boxes (CDR-SB) is scored from 0 to 18. Higher scores reflect worse performance.

    Time frame: Up to 2 years

  7. Alzheimer's Disease Cooperative Study Activities of Daily Living Mild Cognitive Impairment-Activities of Daily Living Inventory (ADCS MCI-ADL)

    The Alzheimer's Disease Cooperative Study Activities of Daily Living-Mild Cognitive Impairment-Activities of Daily Living Inventory (ADCS MCI-ADL) is scored from 0 to 53. Higher scores reflect better performance.

    Time frame: Up to 2 years

  8. Cardiovascular morbidity

    Physician-diagnosed cardiometabolic health disorders will be identified based on ICD-9 or ICD-10 codes (in any position). Any incident cardiometabolic morbidity, for example, ardiac dysrhythmias, heart failure, peripheral and visceral atherosclerosis, non-alcoholic fatty liver disease, chronic kidney disease, type 2 diabetes, hypercholesterolemia, and hypertension, will be recorded.

    Time frame: Up to 2 years

  9. Physical Performance: Grip strength

    Grip strength will be assessed by a hydraulic hand dynamometer and expressed in absolute units(kilograms) andrelative units(kilograms divided by bodyweight).

    Time frame: Up to 2 years

  10. Physical Performance: Gaid speed

    Walking pace will be assessed by the speed (m/second) of completing a 1.5 meters walk.

    Time frame: Up to 2 years

  11. Physical Performance: Balance

    Balance will be measured by standing on one foot and expressed in absolute units(seconds).

    Time frame: Up to 2 years

  12. Physical Performance: Endurance

    Endurance will be assessed by the 2MW. Participants will be asked to "walk as fast as you can without running" for 2 minutes around a 50-foot course. A greater distance(m) indicates better endurance.

    Time frame: Up to 2 years

  13. Physical Performance: Lower limb strength

    Lower limb strength will be assessed by 30 second sit to stand test and expressed by completion times.

    Time frame: Up to 2 years

  14. Quality of Life Questionnaire (15D)

    The Quality of Life Questionnaire (15D) has a single index (15D score) on a 0-1 scale, which represents overall HRQoL (0 = being dead, 0.0162 = being unconscious or comatose, 1 = no problems on any dimension = 'full' HRQOL). This is calculated from the health state descriptive system by using a set of population-based preference or utility weights.

    Time frame: Up to 2 years

  15. The Geriatric Depression Scale (GDS)

    The Geriatric Depression Scale (GDS) is scored from 0 to 15. Scores of 0-4 are considered normal, 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

    Time frame: Up tp 2 years

  16. Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is scored from 0 to 21. Higher scores indicate worse sleep quality.

    Time frame: Up to 2 years

  17. Leisure-Time Activities Questionnaire

    The Leisure-Time Activities Questionnaire measures the frequency of engagement in the following activities: Health activities, Social activities, Productive activities, Fitness activities, Recreational activities, Any cognitively-stimulating activities. Scores are measured on a 3-point scale. Higher scores represent higher frequency of engagement in leisure-time activities.

    Time frame: Up to 2 years

  18. Resource Use Inventory (RUI)

    The Resource Use Inventory (RUI) measures 4 domains: direct medical care, direct nonmedical care, informal care, and subjects' time use. The RUI is filled in based on the frequency and amount of resources used. If none were used, '00' is entered.

    Time frame: Up to 2 years

  19. Hight

    Height will be measured in metres

    Time frame: Up to 2 years

  20. Weight

    Weight will be measured in kilograms.

    Time frame: Up to 2 years

  21. Hip circumference

    Hip circumference will be measured in centimetres.

    Time frame: Up to 2 years

  22. Waist circumference

    Waist circumference will be measured in centimetres.

    Time frame: Up to 2 years

  23. Changes in Blood Pressure

    Vascular and metabolic risk factors measured by changes in blood pressure in mmHg. Incident events using serious adverse event reports will also be assessed.

    Time frame: Up to 2 years

  24. Changes in lipid Profile

    Blood samples will be collected from all patients in tubes with ethylenediaminetetraacetic acid 0.1%. Lipid Profile will be expressed by total cholesterol, LDL-cholesterol, HDL-cholesterol or triglycerides in mmol/L.

    Time frame: Up to 2 years

  25. Changes in Glucose Regulation

    Vascular and metabolic risk factors measured by changes in glucose regulation in mmol/L.

    Time frame: Up to 2 years

  26. Retinal Imaging Markers

    Retinal fundus photographs will be taken of each eye with a nonmydriatic digital camera after dilation of pupils with 1% tropicamide eye drops. A semi-automated computer-assisted program will be used to assess retinal vascular fractal dimensions (among other parameters such as vessel caliber and vessel tortuosity) from optic disc-centered images of a randomly selected eye per participant.

    Time frame: Up to 2 years

  27. Falls

    Prospective rate of falls, causes and consequences via monthly calendar will be recorded.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • School of Public Health and The Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou, China
    Hangzhou, Zhejiang 310000, China
    Recruiting
08

References and documents

Publications

  • Xu X, Chew KA, Wong ZX, Phua AKS, Chong EJY, Teo CKL, Sathe N, Chooi YC, Chia WPF, Henry CJ, Chew E, Wang M, Maier AB, Kandiah N, Chen CL. The SINgapore GERiatric Intervention Study to Reduce Cognitive Decline and Physical Frailty (SINGER): Study Design and Protocol. J Prev Alzheimers Dis. 2022;9(1):40-48. doi: 10.14283/jpad.2022.5. PubMed 35098972 ↗
  • Zhao X, Hu R, Wen H, Xu G, Pang T, He X, Zhang Y, Zhang J, Chen C, Wu X, Xu X. A voice recognition-based digital cognitive screener for dementia detection in the community: Development and validation study. Front Psychiatry. 2022 Jul 22;13:899729. doi: 10.3389/fpsyt.2022.899729. eCollection 2022. PubMed 35935417 ↗

Individual participant data

Plan to share: No — Interested collaborators may put in a request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2023; primary completion for Apr 2025, 23 months later.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 23 months is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
Jun 2, 2023
StartEst.
May 28, 2023
Primary completionEst.
Apr 28, 2025
CompletionEst.
Apr 28, 2027
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05886114
Responsible party
Xin Xu (Prof., Zhejiang University) — Principal investigator
First posted
Jun 2, 2023
Start date
May 28, 2023 (estimated)
Primary completion
Apr 28, 2025 (estimated)
Completion
Apr 28, 2027 (estimated)
Last update
Jun 6, 2023

Study contacts

Xin Xu, PhD
Contact
xuxinsummer@zju.edu.cn
+8613575760802
Changzheng Yuan, PhD
Contact
chy478@zju.edu.cn

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion